NCT01873339View on ClinicalTrials.gov

Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 19, 2013

Primary Completion Date

September 12, 2013

Study Completion Date

September 12, 2013

Conditions
Atherosclerosis
Interventions
DRUG

Darapladib

The subjects will receive darapladib 160 mg once daily on Days 3-14. It is provided as Enteric coated, free base (micronized) 160 mg tablet.

DRUG

Midazolam

The subjects will receive a single oral dose of midazolam 5 mg on Day 1, 3 and14. It is provided as syrup. Each mL of syrup contains midazolam hydrochloride equivalent to 2 mg midazolam

Trial Locations (1)

21225

GSK Investigational Site, Baltimore

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01873339 - Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects | Biotech Hunter | Biotech Hunter